Patient Derived Xenograft Market Size to grow by USD 188.19 mn | Major Vendors Include Champions Oncology Inc. and Charles River Laboratories International Inc. | Technavio

·4 min read

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- The patient derived xenograft market size is anticipated to grow by USD 188.19 mn, progressing at a CAGR of 16.66% during the forecast period. This exclusive market forecast report by Technavio covers market scenarios, estimates, and customer behavior.

Attractive Opportunities in Patient Derived Xenograft Market by Application and Geography - Forecast and Analysis 2021-2025
Attractive Opportunities in Patient Derived Xenograft Market by Application and Geography - Forecast and Analysis 2021-2025

Read Our Free Sample Report to explore growth opportunities in the patient derived xenograft market.

Market Dynamics

The market is driven by factors such as the growing demand for personalized medicine, development of immunodeficient rats, and the increasing incidence of lung cancers. However, stringent government guidelines regarding the ethical use of animals in cancer research and the high cost of patient derived xenograft models are expected to reduce the growth potential in the market.

For additional information on the various trends, drivers, and challenges impacting the market, View a Free Sample Report Now

Company Profiles

The patient derived xenograft market report provides complete insights on key vendors, including Champions Oncology Inc., Charles River Laboratories International Inc., Experimental Pharmacology and Oncology EPO Berlin Buch GmbH, Hera Biolabs Inc., Oncodesign SA, PerkinElmer Inc., The Jackson Laboratory, UROSPHERE SAS, and WuXi AppTec Co. Ltd.

Vendor Landscape

The market in focus was fragmented in 2020. It is expected to remain the same during the forecast period due to the presence of a significant number of global, regional, and local players in the market. Companies adopt various marketing strategies such as mergers and acquisitions to increase their market share. This is going to increase the completion among vendors during the forecast period. However, high capital investment is required to enter the market. This will restrict the entry of new entrants during the forecast period and thereby decrease rivalry in the market.

Competitive Analysis

The competitive scenario provided in the patient derived xenograft market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.

Market Segmentation

  • By application, the market is classified into preclinical drug development and bio marker analysis. The preclinical drug development segment contributes the largest share of the market.

  • By geography, the market is classified into North America, Europe, Asia, and ROW. North America will have the largest share of the market during the forecast period.

Subscribe to our "Lite Plan" billed annually at USD 3000 to view 3 reports monthly and download 3 reports annually.

Related Reports

  • Dental Bone Graft Substitutes Market: The dental bone graft substitutes market has been segmented by end-user (dental clinics and hospitals), type (xenografts, allografts, synthetic bone grafts, and DBM), and geography (Europe, North America, Asia, and ROW). Download Free Sample Report

  • Immunology Market: The immunology market has been segmented by category (immunosuppressants and immuno boosters) and geography (North America, Europe, Asia, and ROW). Download Free Sample Report

Patient Derived Xenograft Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 16.66%

Market growth 2021-2025

USD 188.19 million

Market structure

Fragmented

YoY growth (%)

12.13

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 40%

Key consumer countries

US, Canada, Mexico, Germany, UK, France, China, Japan, and India

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Champions Oncology Inc., Charles River Laboratories International Inc., Experimental Pharmacology and Oncology EPO Berlin Buch GmbH, Hera Biolabs Inc., Oncodesign SA, PerkinElmer Inc., The Jackson Laboratory, UROSPHERE SAS, and WuXi AppTec Co. Ltd.

Market Dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Technavio (PRNewsfoto/Technavio)
Technavio (PRNewsfoto/Technavio)
Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/patient-derived-xenograft-market-size-to-grow-by-usd-188-19-mn--major-vendors-include-champions-oncology-inc-and-charles-river-laboratories-international-inc--technavio-301432325.html

SOURCE Technavio

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting